MedPath

Benzydamine

Generic Name
Benzydamine
Brand Names
Pharixia, Tantum
Drug Type
Small Molecule
Chemical Formula
C19H23N3O
CAS Number
642-72-8
Unique Ingredient Identifier
4O21U048EF

Overview

Benzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system. Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.

Background

Benzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system. Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.

Indication

Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions. When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures. When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures.

Associated Conditions

  • Acute Sore Throat
  • Gingivitis
  • Inflammation of Mouth
  • Laryngitis
  • Mouth irritation
  • Mucositis of the oro-pharyngeal
  • Pain
  • Pain, Orofacial
  • Pharyngitis
  • Sore gums
  • Throat irritation
  • Traumatic Injuries caused by Dental Prosthesis
  • Gum irritation

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

DIFFLAM SOLUTION 22.5 mg/15 ml
Manufacturer:Ensign Laboratories Pty Ltd
Form:MOUTHWASH
Strength:22.5 mg/15 ml
Online:Yes
Approved: 1990/04/23
Approval:SIN04232P
DIFFLAM-C ANTI-INFLAMMATORY ANTISEPTIC SOLUTION
Manufacturer:Ensign Laboratories Pty Ltd
Form:MOUTHWASH
Strength:22.5 mg/15 ml
Online:Yes
Approved: 1996/04/24
Approval:SIN08671P
EASIFLAM MOUTHWASH 0.15% W/V
Manufacturer:Hovid Berhad
Form:MOUTHWASH
Strength:0.15% w/v
Online:Yes
Approved: 2023/05/31
Approval:SIN16801P
Difflam™ Anti-inflammatory Lozenge (with antibacterial) (Eucalyptus and Menthol)
Manufacturer:Unique Pharmaceuticals Laboratories
Form:LOZENGE
Strength:3.0mg
Online:Yes
Approved: 2009/01/22
Approval:SIN13591P
DIFFLAM ANTI-INFLAMMATORY LOZENGE (WITH ANTIBACTERIAL) (HONEY LEMON)
Manufacturer:Unique Pharmaceuticals Laboratories
Form:LOZENGE
Strength:3 mg
Online:Yes
Approved: 2003/06/13
Approval:SIN12320P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath